Difference between revisions of "Team:USP UNIFESP-Brazil/Awards"
MiguelCroce (Talk | contribs) |
MiguelCroce (Talk | contribs) |
||
| Line 50: | Line 50: | ||
<li><a href="https://2016.igem.org/wiki/index.php?title=Team:USP_UNIFESP-Brazil">Home</a></li> | <li><a href="https://2016.igem.org/wiki/index.php?title=Team:USP_UNIFESP-Brazil">Home</a></li> | ||
<li><a href="https://2016.igem.org/Team:USP_UNIFESP-Brazil/Team">Team</a></li> | <li><a href="https://2016.igem.org/Team:USP_UNIFESP-Brazil/Team">Team</a></li> | ||
| − | <li><a href="https://2016.igem.org/Team:USP_UNIFESP-Brazil/Project | + | <li><a href="https://2016.igem.org/Team:USP_UNIFESP-Brazil/Project" >Project</a></li> |
<li><a href="https://2016.igem.org/Team:USP_UNIFESP-Brazil/Parts">Parts</a></li> | <li><a href="https://2016.igem.org/Team:USP_UNIFESP-Brazil/Parts">Parts</a></li> | ||
<li><a href="https://2016.igem.org/Team:USP_UNIFESP-Brazil/Interlab">Interlab</a></li> | <li><a href="https://2016.igem.org/Team:USP_UNIFESP-Brazil/Interlab">Interlab</a></li> | ||
Revision as of 22:22, 17 October 2016
AlgAranha Team USP-UNIFESP BRASIL
The protein structure of spider silk is composed of two constant terminal domains and a variable middle structural domain. Our design uses the substitution of this middle domain by a protein of interest, as used by Team:UCLA in 2014. In our case, we are using enzybiotics.
The protein structure of spider silk is composed of two constant terminal domains and a variable middle structural domain. Our design uses the substitution of this middle domain by a protein of interest, as used by Team:UCLA in 2014. In our case, we are using enzybiotics.
The protein structure of spider silk is composed of two constant terminal domains and a variable middle structural domain. Our design uses the substitution of this middle domain by a protein of interest, as used by Team:UCLA in 2014. In our case, we are using enzybiotics.
The protein structure of spider silk is composed of two constant terminal domains and a variable middle structural domain. Our design uses the substitution of this middle domain by a protein of interest, as used by Team:UCLA in 2014. In our case, we are using enzybiotics.
